Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/797,157

TRANSMITTAL
Filing Date 03/09/2004

First Named Inventor Martin Oft

Art Unit 1646

Examiner Name Dong Jiang

Attorney Docket Number Page 2004

				1040			
(to be used for a	all correspondence after initial	filina)	Examiner Name	Dong Jiang			
	Pages in This Submission	Attorney Docket Number	DX06022L	DX06022US01			
		ENO	LOCUETO (C)				
		ENC	LOSURES (Check all	that apply	<i>(</i>)		
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		Remar	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD Remarks of references cited: 1 of references included: 1		After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):		
	SIGNA	TURE C	F APPLICANT, ATTO	RNEY, C	OR AGE	NT	
Firm Name	DNAX Research, Inc.						
Signature	/Gregory R. Bellomy/ R	eg. No. 48	,451				
Printed name Gregory R. Bellomy							
Date 29 June 2007				Reg. No.	48,451		
	at this correspondence is t as first class mail in an en	eing facsii	CATE OF TRANSMISS mile transmitted to the USPT dressed to: Commissioner fo	O or depos	sited with t		
Signature							
-							
Typed or printed n	iame					Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Attorney Docket: DX06022US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	I
In Re application of:	Examiner: Dong Jiang
Martin Oft, et al.	Art Unit: 1646
Application No.: 10/797,157	Conf. No.: 4687
Filed: March 9, 2004	
For: USES OF IL-23 AGONISTS AND ANTAGONISTS; RELATED	

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REAGENTS

INFORMATION DISCLOSURE STATEMENT

Sir:			
PTO/SE Copy(ie	3/08 fo s) of t	rm be o hese re	Rule 56, it is requested that the documents listed on the accompanying considered and made of record in the above-identified patent application. Ferences are attached were filed in related application U.S. Serial , respectively.
((b)	No fee	is believed due because:
			This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
			This Information Disclosure Statement is being concurrently filed with the above-identified application.
			This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
			This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
((c)		This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
			Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

				No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or
				The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
	(d)	\boxtimes		nformation Disclosure Statement is being filed on or before the ent of the issue fee; and
				Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
				No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
			\boxtimes	The Commissioner is hereby authorized to charge the requisite fee of \$180.
	requir		nis Infor	s hereby authorized to charge any additional fees which may be mation Disclosure Statement, or credit any overpayment to Deposit .
				Respectfully submitted,
Date:	_29 Ju	ine 2007	'	By: /Gregory R. Bellomy/ Gregory R. Bellomy, Reg. No. 48,451 Attorney for Applicants

Customer No. 028008

DNAX Research, Inc. 901 California Avenue Palo Alto, CA 94304-1104

Telephone (Switchboard): (650) 496-6400 Telephone No. (Direct): (650) 496-6565 Facsimile No.: (650) 496-1200

10/797,157 Page 2 of 2 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/797,157	
INFORMATION DISCLOSURE				Filing Date	03/09/2004	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Martin Oft	
	(Use as many she	ets as n	ecessary)	Art Unit	1646	
(esc as many sheets as necessary)			eocoodi y)	Examiner Name	Dong Jiang	
Sheet	1	of	1	Attorney Docket Number	DX06022US01	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	вс	COUSSENS and WERB, Insight review articles: Inflammation and cancer, Nature (2002), Vol. 420, pages 860-867.	
Examiner Signature		Date Considered	

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: